Search academic texts

Information × Registration Number 0219U000973, 0118U003731 , R & D reports Title Improve the treatment of primary lymphoma patients with B cellular origin popup.stage_title Head Kryachok Iryna, Registration Date 21-03-2019 Organization Ukrainian Research Institute of Oncology and Radiology popup.description2 Object of research - non-Hodgkin's lymphomas, immunohistochemical and molecular genetic factors of the disease. The purpose of the work is to determine the role of immunohistochemical and molecular genetic markers in the prognosis of non-Hodzinsky diffuse In-large-cell lymph, optimize the treatment of patients with non-Hodgkin's diffuse V-cell lymphomas using the latest chemotherapy regimens. Research methods and equipment: morphological, immunohistochemical, clinical, statistical, ultrasound apparatus "Aloca", CT. The analysis of the prognostic significance of immunohistochemical and molecular genetic markers for the prognosis of the disease in 349 patients with DVBVKL was conducted. There were no statistically significant differences in the response to therapy between the groups with negative and positive expression of Bcl-6, CD10, CD30, MUM1, and C-Myc in the pairwise comparison with the positive response (PU and PW). The refractory course was reliably more frequently recorded in patients with negative Bcl-6 expression (23.3% vs. 10.9%; p = 0.025), relative risk (BP) for the development of recurrent and refractory disease in patients with DVBVs with negative Bcl-6 expression is 2.15 (95% IU 1.14-4.07; p = 0.05). That is, with negative expression of Bcl-6, the risk of recurrent or refractory flow increased by 2.15 times. The connection of remote results of treatment of patients with DVVKL with factor factors has been analyzed. The constructed linear 6-factor linear neural network model of prediction is adequate and allows for a specificity with 86.0% (95% BI 74.2-93.7%) sensitivity and 62.5% (95% BI 54.9-69.7%) predict survival risk less than 12 months. Based on the analysis of the sign of the indicated model coefficients, the linear approximation found that the presence of positive Bcl-6 expression XL (X1 = 1) and positive CDI expression of CD10 (X2) reduced the risk of early death to 12 months; the non-GCB molecular subtype of non-GCB cells determined by the Hans (X3 = 1) algorithm and the male sex (X4 = 1) increase the risk of early death to 12 months; The third stage of the Ann-Arbor disease (X5 = 1) and the presence of> 2 extranodal lesions (X6 = 1) make it possible to isolate a group of high-risk patients with a predicted survival of less than 12 months. The most important factors of the unfavorable prognosis of the disease in patients with B-cell lymphomas of low degree of malignancy are the level of expression of bcl-2, Ki-67, p-53, pgp, RKS? in tumor cells. It has been established that the expression of bcl-2, Ki-67, p-53, pgp indicates an unfavorable course of the disease. The vast majority of patients who had a positive expression of these markers lived no more than three years or had a recurrent course of the disease. Feedback with RKS? expression was observed: the absence of expression of this marker indicated an unfavorable course of the disease. The effectiveness of treatment for patients with small cell NHL is higher by 27% in the group of patients who were prescribed treatment based on the clinical and immunohistochemical factors of the prognosis of the disease incidence bcl-2, Ki-67, p-53, pgp, РКС?. Patients with unfavorable course of clinical data and the level of expression of bcl-2, Ki-67, p-53, pgp, РКС? need to appoint more aggressive courses of PCT (SNOER, ВСНОР, ВСНОЭР), with favorable course - СНОП. Product Description popup.authors А. Мартинчик Крячок Ірина Анатоліївна О. Алексик Титоренко Ірина Борисівна popup.nrat_date 2020-04-02 Close